Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.0%
    Check dated 2026-03-11T20:20:39.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2; removed the previous notices including Revision: v3.4.1 related to government funding and operating status.
    Difference
    0.3%
    Check dated 2026-02-11T10:15:51.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and the NIH Clinical Center's operating status, and updated the page footer with Revision: v3.4.1 replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-04T06:50:39.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Minor UI/text updates were implemented: the glossary is now shown, the label 'Last Update Submitted that Met QC Criteria' was added/updated, 'No FEAR Act Data' phrasing was corrected, and the revision label updated to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-28T04:25:39.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4.
    Difference
    0.0%
    Check dated 2026-01-14T01:52:15.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added Revision: v3.3.3 at the bottom of the page; removed HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T12:29:52.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.